Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
Clinical Trial 20144
Cancer Type: Head & Neck
Study Type: Treatment
NCT#: NCT03978689
Phase: Phase I
Prinicipal Investigator: Christine Chung
Study Title
A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Summary
This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
Objective
Part A: Dose escalation and expansion of CUE-101 as monotherapy Part B: Dose confirmation Co-primary objectives: > To assess the safety and tolerability of CUE-101 in subjects with recurrent/metastatic HPV16-driven malignancies (HLA-A*0201, HPV16+ disease: HPV 16 genotyping, plus tumor p16+) and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) based on markers of biological activity (biologically effective dose) (Part A) > To evaluate the pharmacokinetics (PK) of CUE-101 when administered in subjects with recurrent/metastatic HPV16-driven malignancies (Parts A and B) Secondary objectives: > To confirm safety and evaluate antitumor activity at the RP2D (Part B) > To assess the preliminary antitumor activity of CUE-101 based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (Parts A and B) > To assess the potential for immune response upon treatment with CUE-101 (Parts A and B) > To assess the potential immunogenicity of CUE-101 (Parts A and B)
Therapies
Medications
CUE-101 (); Pembrolizumab (Keytruda)
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.